Table 2.
Primary Tumor Tissues | Mutations (%) 1 | Copy Number Variations (%) 1 | Gene Expression (%) 1 | ||
---|---|---|---|---|---|
Gain | Loss | Over | Under | ||
Adrenal gland | 0/790 (0%) | - | - | 9/79 (11.39%) | - |
Autonomic ganglia | 0/1442 (0%) | - | - | - | - |
Biliary tract | 20/1898 (1.05%) | - | - | - | - |
Bone | 16/890 (1.8%) | - | - | - | - |
Breast | 490/12,455 (3.93%) | 5/1492 (0.34%) | 2/1492 (0.13%) | 69/1104 (6.25%) | 3/1104 (0.27%) |
– ductal carcinoma | 186/3743 (4.97%) | - | - | - | - |
– ER-positive carcinoma | 71/1475 (4.81%) | - | - | - | - |
– HER-positive carcinoma | 1/301 (0.33%) | - | - | - | - |
– basal (triple-negative) carcinoma | 9/553 (1.63%) | - | - | - | - |
– ER-PR-positive carcinoma | 22/364 (6.04%) | - | - | - | - |
Central nervous system | 15/4711 (0.32%) | 4/1035 (0.39%) | 1/1035 (0.1%) | 22/697 (3.16%) | 43/697 (6.17%) |
Cervix | 11/901 (1.22%) | 1/299 (0.33%) | - | 15/307 (4.89%) | 7/307 (2.28%) |
Endometrium | 58/1575 (3.68%) | 2/586 (0.34%) | - | 49/602 (8.14%) | 6/602 (1%) |
– endometrioid carcinoma | 44/954 (4.61%) | 2/530 (0.38%) | - | 39/545 (7.16%) | 6/545 (1.1%) |
Eye | 1/370 (0.27%) | - | - | - | - |
Gastrointestinal tract | 0/1 (0%) | - | - | - | - |
Hematopoietic and lymphoid | 33/8040 (0.41%) | - | 1/661 (0.15%) | 7/221 (3.17%) | 2/221 (0.9%) |
Kidney | 10/3008 (0.33%) | - | 4/995 (0.4%) | 26/600 (4.33%) | 27/600 (4.5%) |
Large intestine | 147/8066 (1.82%) | - | - | 18/610 (2.95%) | 44/610 (7.21%) |
Liver | 31/2822 (1.1%) | 1/663 (0.15%) | 1/663 (0.15%) | 24/373 (6.43%) | 24/373 (6.43%) |
Lung | 96/11467 (0.84%) | 10/1006 (0.99%) | 2/1006 (0.2%) | 89/1019 (8.73%) | 46/1019 (4.51%) |
– adenocarcinoma | 41/6799 (0.6%) | 4/375 (1.07%) | - | 44/378 (11.64%) | 12/378 (3.17%) |
– non-small cell carcinoma | 4/644 (0.62%) | - | - | - | - |
– squamous cell carcinoma | 18/2138 (0.84%) | 6/500 (1.2%) | - | 37/502 (7.37%) | 26/502 (5.18%) |
Meninges | 269/1766 (15.23%) | - | - | - | - |
Esophagus | 14/2601 (0.54%) | 1/510 (0.2%) | - | 9/125 (7.2%) | - |
Ovary | 32/2012 (1.59%) | 8/684 (1.17%) | - | 33/266 (12.41%) | 6/266 (2.26%) |
Pancreas | 29/3155 (0.92%) | - | - | 10/179 (5.59%) | 8/179 (4.47%) |
Penis | 1/101 (0.99%) | - | - | - | - |
Peritoneum | 3/201 (1.49%) | - | - | - | - |
Pituitary | 0/88 (0%) | - | - | - | - |
Pleura | 1/511 (0.2%) | - | - | - | - |
Prostate | 161/4202 (3.83%) | - | - | 22/498 (4.42%) | 5/498 (1%) |
Salivary gland | 7/535 (1.31%) | - | - | - | - |
Skin | 128/3730 (3.43%) | - | - | 21/473 (4.44%) | - |
Small intestine | 2/315 (0.63%) | - | - | - | - |
Soft tissue | 35/2336 (1.5%) | 1/264 (0.38%) | - | 28/263 (10.65%) | 2/263 (0.76%) |
Stomach | 42/3628 (1.16%) | - | - | 15/285 (5.26%) | 10/285 (3.51%) |
Testis | 2/602 (0.33%) | 1/149 (0.67%) | - | - | - |
Thymus | 1/379 (0.26%) | - | - | - | - |
Thyroid | 39/3657 (1.07%) | - | - | 24/513 (4.68%) | 1/513 (0.19%) |
Upper aerodigestive tract | 27/2621 (1.03%) | 2/520 (0.38%) | - | 63/522 (12.07%) | 23/522 (4.41%) |
Urinary tract | 47/1749 (2.69%) | - | 2/399 (0.5%) | 21/408 (5.15%) | 12/408 (2.94%) |
Vulva | 0/64 (0%) | - | - | - | - |
1 Mutated samples/total number of sample analyzed (%); -, no data. The data were derived from COSMIC v92 (released 27-AUG-20). ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone receptor.